{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T08:34:10Z","timestamp":1726216450516},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1097\/md.0000000000004049","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T11:24:04Z","timestamp":1467631444000},"page":"e4049","source":"Crossref","is-referenced-by-count":5,"title":["CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents"],"prefix":"10.1097","volume":"95","author":[{"given":"Ik Jun","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Seok","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahn-Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Ho","family":"Her","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hun-Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pum-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wook-Sung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Gook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Bae","family":"Seung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyuk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-64-20210309","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-64-20210309","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-0038-1648859","article-title":"The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A","volume":"72","author":"Savi","year":"1994","journal-title":"Thromb Haemost"},{"key":"R3-64-20210309","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1124\/dmd.30.11.1288","article-title":"Structure and stereochemistry of the active metabolite of clopidogrel","volume":"30","author":"Pereillo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"R4-64-20210309","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"R5-64-20210309","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"R6-64-20210309","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"R7-64-20210309","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet"},{"key":"R8-64-20210309","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"R9-64-20210309","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00059-007-2997-9","article-title":"Vascular pathology of drug-eluting stents","volume":"32","author":"Nakazawa","year":"2007","journal-title":"Herz"},{"key":"R10-64-20210309","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(09)62127-9","article-title":"Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial","volume":"375","author":"Kedhi","year":"2010","journal-title":"Lancet"},{"key":"R11-64-20210309","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","article-title":"Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease","volume":"362","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R12-64-20210309","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10554-011-9849-7","article-title":"Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography","volume":"28","author":"Choi","year":"2012","journal-title":"Int J Cardiovasc Imaging"},{"key":"R13-64-20210309","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"R14-64-20210309","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R15-64-20210309","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/hrt.2011.227272","article-title":"Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents","volume":"98","author":"Oh","year":"2012","journal-title":"Heart"},{"key":"R16-64-20210309","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"R17-64-20210309","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/hrt.2011.227652","article-title":"Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel","volume":"98","author":"Zabalza","year":"2012","journal-title":"Heart"},{"key":"R18-64-20210309","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jacc.2012.01.073","article-title":"Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-Year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial","volume":"60","author":"Hofma","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R19-64-20210309","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jacc.2008.04.030","article-title":"Endothelial cell recovery between comparator polymer-based drug-eluting stents","volume":"52","author":"Joner","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R20-64-20210309","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/CIRCINTERVENTIONS.110.957654","article-title":"Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis","volume":"4","author":"Nakazawa","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"R21-64-20210309","doi-asserted-by":"crossref","first-page":"e2062","DOI":"10.1097\/MD.0000000000002062","article-title":"It is not mandatory to use triple rather than dual anti-platelet therapy after a percutaneous coronary intervention with a second-generation drug-eluting stent","volume":"94","author":"Kim","year":"2015","journal-title":"Medicine (Baltimore"},{"key":"R22-64-20210309","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ijcard.2012.10.043","article-title":"Comparisons of detailed arterial healing response at seven months following implantation of an everolimus- or sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction","volume":"168","author":"Sawada","year":"2013","journal-title":"Int J Cardiol"},{"key":"R23-64-20210309","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijcard.2014.11.068","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism on intra-stent thrombi and lesion outcome after everolimus-eluting stent implantation compared to that after first-generation drug-eluting stent implantation","volume":"179","author":"Konishi","year":"2015","journal-title":"Int J Cardiol"},{"key":"R24-64-20210309","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1161\/CIRCGENETICS.113.000109","article-title":"CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina","volume":"6","author":"Kim","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"R25-64-20210309","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.113.001437","article-title":"Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423 965 patients in the linked National Cardiovascular Data Registry and centers for Medicare & Medicaid services payer databases","volume":"127","author":"Kumar","year":"2013","journal-title":"Circulation"},{"key":"R26-64-20210309","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"R27-64-20210309","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehq321","article-title":"CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case\u2013control study","volume":"31","author":"Harmsze","year":"2010","journal-title":"Eur Heart J"},{"key":"R28-64-20210309","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2012.11.015","article-title":"Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries","volume":"61","author":"Park","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000004049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:27:42Z","timestamp":1620959262000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201606280-00064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":28,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004049","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}